Literature DB >> 15980360

Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.

Marybeth A Maligie1, Claude P Selitrennikoff.   

Abstract

(1,3)Beta-D-glucan synthase (EC 2.4.1.34. UDP-glucose: 1,3-beta-D-glucan 3-beta-glucosyltransferase) uses UDP-glucose as substrate and catalyzes the polymerization of glucose ([1,3]-beta-linkages) to form the major carbohydrate component of the fungal cell wall. We have optimized in vitro assay conditions for (1,3)beta-glucan synthase activity from Cryptococcus neoformans. Cells lysed in 50 mM Tris, pH 7.75, containing 20% glycerol, 2 mM NaF, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 5 mM MgCl(2), 0.1% protease and phosphatase inhibitor cocktails, and 60 microM GTPgammaS produced maximum specific activity in vitro. We tested in vitro C. neoformans (1,3)beta-glucan synthase activity against the (1,3)beta-glucan synthase inhibitors, caspofungin and cilofungin, and have determined that (1,3)beta-glucan synthase activity is very sensitive (apparent K(i) of 0.17 +/- 0.02 microM and 22 +/- 5.7 microM, respectively) to these echinocandins. Taken together with high MICs for C. neoformans (caspofungin MIC, 16 microg/ml; cilofungin MIC, 64 microg/ml), our results indicate that C. neoformans is resistant to caspofungin and cilofungin by a mechanism(s) unrelated to (1,3)beta-glucan synthase resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980360      PMCID: PMC1168702          DOI: 10.1128/AAC.49.7.2851-2856.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

Review 1.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Authors:  M S Saag; R J Graybill; R A Larsen; P G Pappas; J R Perfect; W G Powderly; J D Sobel; W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

Review 3.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

Authors:  J E Kaplan; D Hanson; M S Dworkin; T Frederick; J Bertolli; M L Lindegren; S Holmberg; J L Jones
Journal:  Clin Infect Dis       Date:  2000-04       Impact factor: 9.079

4.  Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.

Authors:  M Del Poeta; M C Cruz; M E Cardenas; J R Perfect; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans.

Authors:  M Feldmesser; Y Kress; A Mednick; A Casadevall
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

7.  Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.

Authors:  S K Balani; X Xu; B H Arison; M V Silva; A Gries; F A DeLuna; D Cui; P H Kari; T Ly; C E Hop; R Singh; M A Wallace; D C Dean; J H Lin; P G Pearson; T A Baillie
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

8.  Characterization and optimization of in vitro assay conditions for (1,3)beta-glucan synthase activity from Aspergillus fumigatus and Candida albicans for enzyme inhibition screening.

Authors:  R L Wood; T K Miller; A Wright; P McCarthy; C S Taft; S Pomponi; C P Selitrennikoff
Journal:  J Antibiot (Tokyo)       Date:  1998-07       Impact factor: 2.649

9.  A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.

Authors:  J R Thompson; C M Douglas; W Li; C K Jue; B Pramanik; X Yuan; T H Rude; D L Toffaletti; J R Perfect; M Kurtz
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

10.  Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase.

Authors:  P Mazur; N Morin; W Baginsky; M el-Sherbeini; J A Clemas; J B Nielsen; F Foor
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

View more
  68 in total

1.  Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence.

Authors:  Amy J Reese; Aki Yoneda; Julia A Breger; Anne Beauvais; Hong Liu; Cara L Griffith; Indrani Bose; Myoung-Ju Kim; Colleen Skau; Sarah Yang; Julianne A Sefko; Masako Osumi; Jean-Paul Latge; Eleftherios Mylonakis; Tamara L Doering
Journal:  Mol Microbiol       Date:  2007-03       Impact factor: 3.501

Review 2.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

Review 3.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

4.  A novel specificity protein 1 (SP1)-like gene regulating protein kinase C-1 (Pkc1)-dependent cell wall integrity and virulence factors in Cryptococcus neoformans.

Authors:  Amos Adler; Yoon-Dong Park; Peter Larsen; Vijayaraj Nagarajan; Kurt Wollenberg; Jin Qiu; Timothy G Myers; Peter R Williamson
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 5.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

6.  Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.

Authors:  Wendy W J van de Sande; Ahmed H Fahal; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

7.  A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans.

Authors:  Isaac R Banks; Charles A Specht; Maureen J Donlin; Kimberly J Gerik; Stuart M Levitz; Jennifer K Lodge
Journal:  Eukaryot Cell       Date:  2005-11

8.  Creation, characterization and utilization of Cryptococcus neoformans mutants sensitive to micafungin.

Authors:  Akio Toh-E; Misako Ohkusu; Kiminori Shimizu; Masashi Yamaguchi; Naruhiko Ishiwada; Akira Watanabe; Katsuhiko Kamei
Journal:  Curr Genet       Date:  2017-05-30       Impact factor: 3.886

Review 9.  Antifungal drug resistance: evolution, mechanisms and impact.

Authors:  Nicole M Revie; Kali R Iyer; Nicole Robbins; Leah E Cowen
Journal:  Curr Opin Microbiol       Date:  2018-03-13       Impact factor: 7.934

Review 10.  How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.

Authors:  Tamara Lea Doering
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.